- Home
- SOWG vs AXDX Comparison
SOWG vs AXDX Comparison
Compare SOWG & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- AXDX
- Stock Information
- Founded
- SOWG 2010
- AXDX 1982
- Country
- SOWG United States
- AXDX United States
- Employees
- SOWG N/A
- AXDX N/A
- Industry
- SOWG Packaged Foods
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- SOWG Consumer Staples
- AXDX Industrials
- Exchange
- SOWG Nasdaq
- AXDX Nasdaq
- Market Cap
- SOWG 22.6M
- AXDX 27.0M
- IPO Year
- SOWG N/A
- AXDX 1996
- Fundamental
- Price
- SOWG $2.43
- AXDX $1.19
- Analyst Decision
- SOWG Strong Buy
- AXDX Hold
- Analyst Count
- SOWG 2
- AXDX 1
- Target Price
- SOWG $23.00
- AXDX $1.00
- AVG Volume (30 Days)
- SOWG 33.8K
- AXDX 21.6K
- Earning Date
- SOWG 03-21-2025
- AXDX 05-07-2025
- Dividend Yield
- SOWG N/A
- AXDX N/A
- EPS Growth
- SOWG N/A
- AXDX N/A
- EPS
- SOWG 0.21
- AXDX N/A
- Revenue
- SOWG $40,130,971.00
- AXDX $11,909,000.00
- Revenue This Year
- SOWG $122.17
- AXDX $0.66
- Revenue Next Year
- SOWG N/A
- AXDX $3.36
- P/E Ratio
- SOWG $11.63
- AXDX N/A
- Revenue Growth
- SOWG 508.45
- AXDX N/A
- 52 Week Low
- SOWG $1.98
- AXDX $0.73
- 52 Week High
- SOWG $24.83
- AXDX $2.09
- Technical
- Relative Strength Index (RSI)
- SOWG 46.21
- AXDX 55.04
- Support Level
- SOWG $2.20
- AXDX $1.04
- Resistance Level
- SOWG $2.36
- AXDX $1.14
- Average True Range (ATR)
- SOWG 0.19
- AXDX 0.08
- MACD
- SOWG 0.01
- AXDX 0.01
- Stochastic Oscillator
- SOWG 47.13
- AXDX 88.17
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free granola products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.